Overview

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Status:
Terminated

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy. SLM may help prevent or reduce mucositis, or mouth sores, in patients receiving chemotherapy and radiation therapy. It is not yet known whether SLM is more effective than a placebo in reducing mucositis

Phase:

Phase 2

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cisplatin
Selenium